Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Monday that the European Commission has approved Imfinzi (durvalumab) as the first immunotherapy for adults with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression following platinum-based chemoradiation therapy.
This approval is based on the ADRIATIC Phase III trial, which demonstrated a 27% reduction in the risk of death for Imfinzi versus placebo. Median overall survival was 55.9 months for Imfinzi compared to 33.4 months for placebo, with 57% of Imfinzi-treated patients alive at three years versus 48% for placebo.
Imfinzi also reduced the risk of disease progression or death by 24%, with a median progression-free survival of 16.6 months versus 9.2 months for placebo. The safety profile was consistent with previous findings, with no new safety concerns observed.
Suresh Senan, principal investigator of the ADRIATIC trial, described the approval as a "turning point" for LS-SCLC treatment, while AstraZeneca executive Dave Fredrickson highlighted Imfinzi's role in transforming patient outcomes.
Already approved in the United States and other markets, Imfinzi is under regulatory review in Japan and additional countries for LS-SCLC. It is also approved in combination with chemotherapy for extensive-stage SCLC based on the CASPIAN trial.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025